Search research articles
Contact Us
Filters
Showing results (81-90 of 106) with videos related to
Page
of 11
Sort By:
Research Square
|
September 8, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Plos One
|
February 21, 2009
International network for comparison of HIV neutralization assays: the NeutNet report
Eva Maria Fenyö, Alan Heath, Stefania Dispinseri, et al.
Scientific Reports
|
December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Journal of Virology
|
March 8, 2013
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes
Simon Hoffenberg, Rebecca Powell, Alexei Carpov, et al.
Immunity
|
May 19, 2016
Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch
Daniel T MacLeod, Nancy M Choi, Bryan Briney, et al.
Science Translational Medicine
|
June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Sharon A Riddler, Michael Para, Constance A Benson, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2023
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
Amanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Msphere
|
August 25, 2021
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
Alena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Science (New York, N.Y.)
|
September 5, 2009
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
Laura M Walker, Sanjay K Phogat, Po-Ying Chan-Hui, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 106) with videos related to
Sort By:
Page
of 11
Research Square
|
September 8, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Plos One
|
February 21, 2009
International network for comparison of HIV neutralization assays: the NeutNet report
Eva Maria Fenyö, Alan Heath, Stefania Dispinseri, et al.
Scientific Reports
|
December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Journal of Virology
|
March 8, 2013
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes
Simon Hoffenberg, Rebecca Powell, Alexei Carpov, et al.
Immunity
|
May 19, 2016
Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch
Daniel T MacLeod, Nancy M Choi, Bryan Briney, et al.
Science Translational Medicine
|
June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Sharon A Riddler, Michael Para, Constance A Benson, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2023
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
Amanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Msphere
|
August 25, 2021
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
Alena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Science (New York, N.Y.)
|
September 5, 2009
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
Laura M Walker, Sanjay K Phogat, Po-Ying Chan-Hui, et al.
Page
of 11